[1]
Y. Toi, “Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study: BSA and nintedanib reduction/discontinuation”, Sarcoidosis VDLD, vol. 36, no. 1, pp. 74–78, Mar. 2019.